|Bid||12.16 x 50000|
|Ask||11.68 x 81200|
|Day's Range||10.44 - 12.00|
|52 Week Range||2.06 - 12.00|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Saint Herblain (France), May 19, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirmed that the European Medicines Agency (“EMA”) has accepted the filing of a marketing authorization application (MAA) for Valneva’s inactivated, whole-virus COVID-19 vaccine candidate, VLA2001. Acceptance of the MAA means VLA2001 is advancing from the rolling review process and beginning the formal review process by the EMA’s Committee for Human Medicinal Products (CHM
Per the agreement with the European Commission, Valneva (VALN) has 30 days from May 13, 2022 to win a marketing authorization in the EU for its COVID vaccine or offer an acceptable remediation plan.
Although optimists currently believe we're getting past the worst of the coronavirus pandemic, Dynavax Technologies (NASDAQ: DVAX) shares saw a lift Monday on positive vaccine news. A popular coronavirus stock in the worst days of the outbreak, an important business partner of the company had some good regulatory news to impart. Dynavax investors took this to heart by pushing their company's stock up by nearly 2.3% on the day, while the S&P 500 index sank by 0.4%.